You are hereBiblio / Bring nanomedicines to market: regulatory challenges, opportunities, and uncertainties

Bring nanomedicines to market: regulatory challenges, opportunities, and uncertainties


By csep - Posted on 09 August 2010

TitleBring nanomedicines to market: regulatory challenges, opportunities, and uncertainties
Publication TypeJournal Article
Year of Publication2006
AuthorsNijhara, Ruchika, and Balakrishnan Kishna
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume2
Start Page127
Issue2
Pagination127-136
Date Published06/2006
PublisherElsevier
Publication LanguageEnglish
ISSN Number1549-9634
Abstract

The authors of this article review the major physiochemical, biologic, and functional characteristics of several nanomedicine products currently in use to explore what makes these products unique and a commercial success. The main benefits of the products reviewed are that they provide drugs with site-specific therapeutic action and its ability to reduce potential side-effects. The authors then go on to look at some of the regulatory compliance challenges faced by nanodrugs, and looks at the major stages that the drugs will have to go through for approval by the U.S. Food and Drug Administration. The article reviews these challenges in detail, and finishes with giving synopses of two major drugs that have already gone through the approval process, Rapamune and Abraxane, and looks at why these drugs made it through successfully.